The popularity of endurance events, such as marathons, bike races, and triathlons, has risen steadily over the past 25 years—and with an increased interest in health, fitness, and competition amid the pandemic, that number is expected to continue to increase. The Lymphoma Research Foundation (LRF) has seen a similar increase in interest
from its donors.
The Lymphoma Research Foundation (LRF) has awarded 29 new research grants totaling more than $5.7 million to scientists working at the world’s leading cancer research institutions.
Remembering Bruce Johnson.
The U.S. Food and Drug Administration Approves Axicabtagene Ciloeucel (YESCARTA) for Diffuse Large B-Cell Lymphoma On April 1, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloeucel (YESCARTA, Kite, a Gilead Company),…
Dr. Anita Kumar is a medical oncologist at
Memorial Sloan Kettering Cancer Center (MSK)
and Regional Care Network Medical Site Director at MSK Basking Ridge, N.J.
Dr. Eduardo Sotomayor is embarking on a new and exciting challenge
in his career that will combine his pioneering work in cancer
immunology and dedication to providing quality cancer care for all
patients.
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting, with more than 70 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, presenting abstracts at the conference.
Investigation into the use of chimeric antigen receptor (CAR) T cell therapies has expanded rapidly in recent years, including for hematologic malignancies. Results from several key studies were presented at the 2021 Annual ASH Meeting, which demonstrated the use of these emerging therapies in multiple lines of therapy, new disease states, and using novel constructs to enhance responses.
In the phase III POLARIX study, a team of investigators led by LRF Scientific Advisory Board (SAB) member Christopher R. Flowers, MD, MSc of the University of Texas MD Anderson Cancer Center compared the efficacy of standard R-CHOP with that of a modified drug regimen, in which vincristine was replaced with the antibody-drug conjugate polatuzumab vedotin (pola-R-CHP).
A recurrent mutation in BTG1 is associated with a “super- competitive” B-cell phenotype in both mice and humans and may promote the development of aggressive diffuse large B-cell lymphoma (DLBCL), according to research, funded in part by LRF, presented by LRF grantee Coraline Mlynarczyk, PhD, of Weill Cornell Medicine.
